Skip to main content

Table 2 Association between DASH-E and VAS-P by treatment

From: Platelet-rich plasma versus lidocaine as tenotomy adjuvants in people with elbow epicondylopathy: a randomized controlled trial

VAS-P

DASH-E

Basal

6 weeks

3 months

6 months

12 months

Basal, r (n)

0.28* (33)

0.52* (35)

0.59* (25)

0.26 (28)

0.42* (26)

0.28 (27)

0.46* (25)

0.24 (25)

0.16 (25)

0.25 (24)

6 weeks, r (n)

0.26 (28)

0.34 (32)

0.70* (24)

0.83* (28)

0.63* (24)

0.67* (25)

0.48*(22)

0.47* (23)

0.37 (24)

0.45* (22)

3 months, r (n)

0.23 (27)

0.21 (29)

0.53* (23)

0.60* (24)

0.74* (25)

0.79* (27)

0.63* (23)

0.77* (23)

0.51*(23)

0.76* (20)

6 months, r (n)

0.34* (27)

0.20 (27)

0.56* (22)

0.63* (22)

0.67* (23)

0.84* (25)

0.94* (24)

0.88* (23)

0.73* (23)

0.79* (21)

12 months, r (n)

0.11 (24)

0.07 (23)

0.32 (21)

0.42*(18)

0.34 (22)

0.50*(21)

0.64* (21)

0.63* (20)

0.91* (24)

0.77* (20)

  1. Data without italics represent lidocaine; data with italics represent PRP
  2. DASH-E Spanish version of the Disabilities of the Arm, Shoulder and Hand questionnaires, r Spearman’s rank correlation coefficient, VAS-P visual analogue scale for pain assessment
  3. *p < 0.05
  4. Boldface and bold italics represent statistically significative associations